Eterna Therapeutics (ERNA) filed a registration statement on Wednesday for the resale of about 57 million common shares by certain selling shareholders.
The company said 47.7 million shares are issued and outstanding, while the remaining are issuable on exercise of pre-funded warrants at an exercise price of $0.005.
Eterna will not receive any proceeds from the sale of shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.